Applying Evidence to Individual Patients with Multimorbidity

Similar documents
Evidenced Based Therapy Practice within the BOP. Presented by: CDR Eric Payne, DPT, OCS

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

THE NHS HEALTH CHECK AND INSURANCE FREQUENTLY ASKED QUESTIONS

Stroke Care First week

CARDIA 288 MONTH FOLLOW-UP SUPPLEMENTAL FORM (FORM B) HOSPITALIZATION CASE #: INTERVIEWER ID FY288BIVID2. Page 1 of 6 FY288BH4CN

Coding in Germany - The Use of ICD-10 for Diagnoses

Complete coverage. Unbeatable value.

Main Effect of Screening for Coronary Artery Disease Using CT

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

HEALTH NEWS PROSTATE CANCER THE PROSTATE

The Role of Boards of Management in Clinical Governance. Professor Alan Wolff Wimmera Health Care Group October 2015

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

Cardiovascular Risk in Diabetes

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

Identifying and treating long-term kidney problems (chronic kidney disease)

Group Benefits Evidence of Insurability for Comprehensive Optional Critical Illness Insurance

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

F A S T. Transient ischaemic attack (TIA)

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

DIABETES CARE. Advice. Blood Pressure. Cholesterol. Diabetes control. Eyes. Feet. Guardian Drugs

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

Multimorbidity in patients with type 2 diabetes mellitus in the Basque Country (Spain)

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

Traveller s medical appraisal form

Depression in Older Persons

APPLICATION FOR MEDICARE SUPPLEMENT COVERAGE

Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

Themes. Why is waste in research an ethical issue? Waste occurs in all stages of research. Research funding is finite

Medical Surgical Nursing (Elsevier)

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

A. Ketorolac*** B. Naproxen C. Ibuprofen D. Celecoxib

Vertebrobasilar Disease

09/05/2014. Painting pictures of the brain with numbers. Overview

SUPPLEMENTARY MATERIALS. Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

ECONOMIC COSTS OF PHYSICAL INACTIVITY

AA Life Insurance providing access to Best Doctors. AA Life Insurance is provided by Friends Life and Pensions Limited

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Access to over 53,000 of the world s leading medical experts, from your first day of cover.

New Anticoagulants and GI bleeding

CENTRAL STATES INDEMNITY CO. OF OMAHA Home Office: Omaha, NE Administration: P.O. Box Clearwater, Florida

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

CARE GUIDELINES FROM MCG

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

WHY DO MY LEGS HURT? Veins, arteries, and other stuff.

Antiplatelet therapy:

New Patient Evaluation


Patient Centered Research for the Complex Patient: Older adults with multiple and complex conditions. Mary Tinetti ECRI November, 2014

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo

Rehabilitation. Care

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Early Prostate Cancer: Questions and Answers. Key Points

Comparative Effectiveness Research and Medical Devices in the Healthcare Environment

Living with Atrial Fibrillation: RELATIONSHIPS

Global Objectives. Use of the NIH Stroke Scale (NIHSS) in Emergency Department Patients with Acute Stroke. Why Do This Exercise? Session Objectives

Drug Treatment Considerations In The Elderly

National Sentinel Stroke Audit Phase I (organisational audit) 2006 Phase II (clinical audit) Report for England, Wales and Northern Ireland

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation

Evidence Based Medicine Health Information Infrastructure Transparency and Payment Reform. Ward B. Hurlburt, M.D. October 12, 2002

PHYSICIAN ORDERS TRANSIENT ISCHEMIC ATTACK (TIA) OBSERVATION

Stroke Coding Issues Presentation to: NorthEast Cerebrovascular Consortium

Facts about Zurich Claims. Zurich Life Risk

Group Long Term Care Insurance Application Evidence of Insurability

ALBERTA PROVINCIAL STROKE STRATEGY (APSS)

Group Critical Illness Insurance Provides lump-sum cash benefits that can help with daily expenses

Poole Hospital NHS Foundation Trust Report template

LifeProtect. Serious illness cover. Protecting YOU FROM THE BIGGEST RISKS YOU LL FACE

How To Be A Health Care Leader

AHA/ASA Ischemic Stroke Performance Measures

IMR ISSUES, DECISIONS AND RATIONALES The Final Determination was based on decisions for the disputed items/services set forth below:

Chapter 2 Applications of Prediction Models

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

Group Long Term Care Insurance Application Evidence of Insurability

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk

Using EHRs for Heart Failure Therapy Recommendation Using Multidimensional Patient Similarity Analytics

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s)

STROKE SERIES SS10. Understanding thrombolysis treatment For stroke

How To Treat Dyslipidemia

DRMC NURSE INTERNSHIP Summer 2005 LIBRARY TRAINING ASSIGNMENT I. With a partner: Find and review patient education handouts on the topic below

What is an NNT? What is...? series Second edition Statistics. Supported by sanofi-aventis

TAKING CARE OF YOUR RHEUMATOID ARTHRITIS

Milliman Medical Underwriting Suite

COLORECTAL CANCER SCREENING

Rx Updates New Guidelines, New Medications What You Need to Know

Bone Basics National Osteoporosis Foundation 2013

Chronic diseases in low and middle income countries: more research or more action? Shah Ebrahim London School of Hygiene & Tropical Medicine

The Independent Order Of Foresters ( Foresters ) Critical Illness Rider (Accelerated Death Benefit) Disclosure at the Time of Application

Background & Significance

Assessment of depression in adults in primary care

Transcription:

Applying Evidence to Individual Patients with Multimorbidity Paul Glasziou, Bond University, Australia?

Evidence-informed medicine: Evidence-based medicine is the integration of best research evidence with clinical expertise and patient values - Dave Sackett Patient Concerns Clinical Expertise Best Research

Overview With Co-morbidities the principles of decision making the same but, more complex:

Overview With Co-morbidities the principles of decision making the same but, more complex: Need to consider problem priorities Interactions (disease, drug) may alter Prognosis, benefits or harms Available data usually weaker

Clinical Decision in Comorbidity Understand circumstances, function, and goals of patient Assess patient/problem priorities Decision for individual problem

Clinical Decision in Comorbidity Understand circumstances, function, and goals of patient Assess patient/problem priorities Decision for individual problem

A general model for treatment decisions Higher risk patients (usually) have higher benefits Lower risk patients (usually) have lower benefits Benefit (trial) outcome A. Threshold Co-morbidities May alter the risk/severity, benefits or harms harm Low Severity / risk high Glasziou, Irwig BMJ, 1995

1. Should Mr RM buy an electric toothbrush? 72 year old deaf pensioner Benign Prostatic Hypertrophy Parkinson s Disease gingivitis and frequent caries Trials in young healthy people show improvements in gingivitis scores (but not caries). Questions 1. Would the electric brush work for him? 2. What factors influence your & his decision?

1. Should Mr RM buy an electric toothbrush? 72 year old deaf pensioner Benign Prostatic Hypertrophy Parkinson s Disease gingivitis and frequent caries Trials in young healthy people show improvements in gingivitis scores (but not caries). Questions 1. Would the electric brush work for him? 2. What factors influence your & his decision?

Electric toothbrushes Are they effective? Yes for university students No patients with Parkinson s disease

Trials of toothbrushing in all diseases? Diagnosis Pro (www.diagnosispro.com) 13,000 diseases;

Should Mr RM buy an electric toothbrush? Option 1: new evidence Do an n-of-1 trial? Left side: Electric Right side: Normal

Should Mr RM buy an electric toothbrush? Option 2: reasonable extrapolation outcome The Studies mechanism Harm/cost Benefit (trial) Disease interaction Low Severity / risk high Prognosis interaction

2. Are statins worthwhile for this patient with a history of TIA? 81 year old male with: 1. Transient ischemic attacks (TIA) 2. Non-H.pylori ulcers & Severe GERD 3. NSAID intolerance 4. Chronic neck pain CT scan shows small infarcts Cholesterol normal 5.8mmol/l Should he be taking a statin?

TIA treatments and interaction with co-morbidities TIA treatments Low-dose Aspirin BP-lowering Statin Neck OA NSAID - - GERD - - - Ulcers Intolerant; Use clopidogrel - -

Do statins work in those with a history (Hx) of stroke? Subgroup Analysis Not different (Circulation. 2001;103:387-392.)

How does predicted risk change the benefit? Baseline Risk Relative Risk Reduction Absolute Risk Reduction Number needed to Treat 8% 25% 2% 50 Trial patients

How does predicted risk change the benefit? Baseline Risk Relative Risk Reduction Absolute Risk Reduction Number needed to Treat 20% 25% 5% 20 High risk patient 8% 25% 2% 50 Trial patients 4% 25% 1% 100 1% 25%.25% 400 Typical patients Low risk patient For biological effect & transferability For clinical decision making

2. Are statins worthwhile for this patient with a history of TIA? Benefit (trial) outcome The Studies Sub-group data Harm/cost Low Severity / risk high

3. Fractured hip and carotid stenosis A 92 year old man with bilateral carotid stenosis fell and fractured his hip. The fracture needs a hip replacement but the carotid stenosis puts him at high risk. What should be done? (benefit same; increased harm; patient s priorities crucial)

Summary: Steps from trials to individual decisions 1. What are the benefits and harms? 2. How do co-morbidities change the benefits or the harms? 3. Is the predicted net benefit a worthwhile priority? Benefit (trial) A. Threshold(s) outcome Benefit (attenuated) harm Low Severity / risk high

Take home messages With Co-morbidities the principles of decision making the same but, more complex: Need to consider problem priorities Interactions (disease, drug) may alter Prognosis, benefits or harms Available data usually weaker